2022-05-01 2023-04-30 false Capium Accounts Production 1.1 11964743 bus:FullAccounts 2022-05-01 2023-04-30 11964743 bus:FRS102 2022-05-01 2023-04-30 11964743 bus:AuditExemptWithAccountantsReport 2022-05-01 2023-04-30 11964743 bus:SmallCompaniesRegimeForAccounts 2022-05-01 2023-04-30 11964743 bus:PrivateLimitedCompanyLtd 2022-05-01 2023-04-30 11964743 2022-05-01 2023-04-30 11964743 2023-04-30 11964743 bus:RegisteredOffice 2022-05-01 2023-04-30 11964743 core:WithinOneYear 2023-04-30 11964743 core:AfterOneYear 2023-04-30 11964743 bus:Director1 2022-05-01 2023-04-30 11964743 bus:Director1 2023-04-30 11964743 bus:Director1 2021-05-01 2022-04-30 11964743 2021-05-01 11964743 bus:CompanySecretary1 2022-05-01 2023-04-30 11964743 bus:LeadAgentIfApplicable 2022-05-01 2023-04-30 11964743 2021-05-01 2022-04-30 11964743 2022-04-30 11964743 core:WithinOneYear 2022-04-30 11964743 core:AfterOneYear 2022-04-30 11964743 bus:EntityAccountantsOrAuditors 2021-05-01 2022-04-30 11964743 bus:OrdinaryShareClass1 2022-05-01 2023-04-30 11964743 bus:OrdinaryShareClass1 2023-04-30 11964743 bus:OrdinaryShareClass1 2021-05-01 2022-04-30 11964743 bus:OrdinaryShareClass1 2022-04-30 11964743 core:ComputerEquipment 2022-05-01 2023-04-30 11964743 core:ComputerEquipment 2023-04-30 11964743 core:ComputerEquipment 2022-04-30 11964743 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-04-30 11964743 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2022-04-30 11964743 core:CostValuation core:Non-currentFinancialInstruments 2023-04-30 11964743 core:CostValuation core:Non-currentFinancialInstruments 2022-04-30 11964743 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-04-30 11964743 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2023-04-30 11964743 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2023-04-30 11964743 core:Non-currentFinancialInstruments 2023-04-30 11964743 core:Non-currentFinancialInstruments 2022-04-30 11964743 core:ShareCapital 2023-04-30 11964743 core:ShareCapital 2022-04-30 11964743 core:RetainedEarningsAccumulatedLosses 2023-04-30 11964743 core:RetainedEarningsAccumulatedLosses 2022-04-30 11964743 dpl:Item1 2022-05-01 11964743 dpl:Item1 2023-04-30 11964743 dpl:Item1 2021-05-01 11964743 dpl:Item1 2022-04-30 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 11964743
England and Wales

 

 

 

APOLLO EYE MEDICAL LIMITED


Unaudited Financial Statements
 


Period of accounts

Start date: 01 May 2022

End date: 30 April 2023
Director's report and financial statements
The director presents his/her/their annual report and the financial statements for the year ended 30 April 2023.
Principal activities
Principal activity of the company during the financial year was of Medical Consultancy.
Director
The director who served the company throughout the year was as follows:
Obeda Kailani (from 26/04/2019)
Statement of director's responsibilities
The director is responsible for preparing the directors' report and the financial statements in accordance with applicable law and regulations and in accordance with United Kingdom Generally Accepted Accounting Practice.
Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (Financial Reporting Standard 102). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.
In preparing these financial statements, the director is required to :
  • select suitable accounting policies and then apply them consistently
  • make judgements and accounting estimates that are reasonable and prudent
  • state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements and
  • prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom, governing the preparation and dissemination of financial statements, may differ from legislation in other jurisdictions

On behalf of the board.


----------------------------------
Obeda Kailani
Director

Date approved: 31 January 2024
1
 
 
Notes
 
2023
£
  2022
£
Fixed assets      
Tangible fixed assets 3 4,010    5,611 
4,010    5,611 
Current assets      
Cash at bank and in hand 283    6,929 
Creditors: amount falling due within one year 4 (1,950)   (975)
Net current liabilities (1,667)   5,954 
 
Total assets less current liabilities 2,343    11,565 
Creditors: amount falling due after more than one year 5 (34,509)   (40,164)
Net liabilities (32,166)   (28,599)
 

Capital and reserves
     
Called up share capital 6 100    100 
Profit and loss account (32,266)   (28,699)
Shareholder's funds (32,166)   (28,599)
 


For the year ended 30 April 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of Part 15 of the Companies Act 2006. In accordance with Section 444 of the Companies Act 2006, the profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 31 January 2024 and were signed by:


-------------------------------
Obeda Kailani
Director
2
General Information
APOLLO EYE MEDICAL LIMITED is a private company, limited by shares, registered in England and Wales, registration number 11964743, registration address 10 Cameron Road , Ground Floor Front , Seven Kings , England , IG3 8LA .

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 5 Years Straight Line
2.

Average number of employees

Average number of employees during the year was 0 (2022 : 0).
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 May 2022 8,006    8,006 
Additions  
Disposals  
At 30 April 2023 8,006    8,006 
Depreciation
At 01 May 2022 2,395    2,395 
Charge for year 1,601    1,601 
On disposals  
At 30 April 2023 3,996    3,996 
Net book values
Closing balance as at 30 April 2023 4,010    4,010 
Opening balance as at 01 May 2022 5,611    5,611 


4.

Creditors: amount falling due within one year

2023
£
  2022
£
Accrued Expenses 1,950    975 
1,950    975 

5.

Creditors: amount falling due after more than one year

2023
£
  2022
£
Bank Loans & Overdrafts 34,197    40,039 
Directors' Loan Accounts 312    125 
34,509    40,164 

6.

Share Capital

Authorised
100 Class A shares of £1.00 each
Allotted, called up and fully paid
2023
£
  2022
£
100 Class A shares of £1.00 each 100    100 
100    100 

3